Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | PTPRC | P08575 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30502823 | 1.00 | KMT2A (0.52) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| SCHEMBL29405048 | 0.98 | PTPRC (0.53) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| SCHEMBL11067965 | 0.84 | PTPRC (0.35) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| SCHEMBL5518101 | 0.77 | ADORA2A (0.59) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL25435302 | 0.72 | MAPK8 (0.32) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| Anthraquinone SCHEMBL1901249 | 0.72 | MEN1 (1.00) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| Anthraquinone SCHEMBL14943 | 0.72 | MEN1 (1.00) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| Anthraquinone SCHEMBL29358690 | 0.72 | MEN1 (1.00) | KMT2AMEN1CDC25BALDH1A1MAPT | |
| SCHEMBL6003624 | 0.71 | ALDH1A1 (0.40) | ALDH1A1MAPTNPC1KDM4ECYP3A4 | |
| SCHEMBL69772 | 0.71 | PTPRC (0.91) | KMT2AMEN1CDC25BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1071668-B1 | 5-AMINOINDENO[1,2-C]PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-06-03 | — | — | EP | claimed |
| JP-60156674-A | — | — | None | — | — | JP | disclosed |
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-6407103-B2 | POTENT ENZYME INHIBITORS OF CYCLIN-DEPENDENT KINASES RELATING TO THE CATALYTIC SUBUNITS CDK1-9 AND THEIR REGULATORY SUBUNITS CYCLINS A-H; ANTIPROLIFERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; VIRICIDES; MODULATORS OF DNA/RNA BIOSYNTHESIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-6407103-B2 | POTENT ENZYME INHIBITORS OF CYCLIN-DEPENDENT KINASES RELATING TO THE CATALYTIC SUBUNITS CDK1-9 AND THEIR REGULATORY SUBUNITS CYCLINS A-H; ANTIPROLIFERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; VIRICIDES; MODULATORS OF DNA/RNA BIOSYNTHESIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| WO-2002046182-A1 | SEMICARBAZIDES AND THEIR USES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | DUPONT PHARMACEUTICALS COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | DUPONT PHARMACEUTICALS COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-6291504-B1 | POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES | DUPONT PHARMACEUTICALS COMPANY | 2001-09-18 | — | — | US | disclosed |
| US-6291504-B1 | POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES | DUPONT PHARMACEUTICALS COMPANY | 2001-09-18 | — | — | US | disclosed |
| US-6025301-A | BROAD SPECTRUM HERBICIDES EFFECTIVE AGAINST BOTH MONOCOT AND DICOT WEED SPECIES IN POSTEMERGENCE APPLICATIONS | ROHM AND HAAS COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0862860-A2 | Indanone herbicide compositions and use thereof | ROHM AND HAAS COMPANY (US) | 1998-09-09 | — | — | EP | disclosed |
| JP-S60156674-A | INDENO(1,2-C)PYRAZOL-4(2H)-ONE DERIVATIVE, ITS PREPARATION, AND CARCINOSTATIC AGENT CONTAINING IT AS ACTIVE INGREDIENT | MORISHITA SEIYAKU KK | 1985-08-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | CDK1, CCNA1, CDK19 | KMT2A 1836/4885MEN1 2190/4885CDC25B 56/4885 |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | KMT2A 2875/4885MEN1 667/4885CDC25B 638/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | KMT2A 2868/4885MEN1 551/4885CDC25B 836/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | KMT2A 2918/4885MEN1 1379/4885CDC25B 684/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | KMT2A 2868/4885MEN1 551/4885CDC25B 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.